Navigation Links
Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
Date:3/18/2008

PALO ALTO, Calif., March 18 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that it has expanded its senior debt under an agreement with an affiliate of Lehman Brothers and certain of the other holders of Jazz Pharmaceuticals' existing senior debt. The transaction closed with $40 million of gross proceeds, expanding the senior debt outstanding from $80 million to $120 million. The notes issued under the note and warrant purchase agreement bear interest at 15 percent per annum, payable quarterly in arrears, and are due in June 2011. In connection with this expansion, Jazz Pharmaceuticals issued to the note purchasers five-year warrants to purchase an aggregate of 562,192 shares of its common stock at an exercise price of $14.23 per share.

Jazz Pharmaceuticals has an option under the agreement, through January 31, 2009, to borrow an additional $30 million, with the issuance of additional warrants, if sales of the company's products reach certain levels by the end of 2008 and subject to customary closing conditions.

"We are pleased to have closed this significant expansion of our senior debt with Jazz Pharmaceuticals' senior lenders very quickly after the FDA's approval of LUVOX CR, together with obtaining an option for additional expansion following sales growth of our products," said Matthew K. Fust, Chief Financial Officer.

Jazz Pharmaceuticals plans to use the proceeds of the debt expansion to pay milestones due under its license agreement with Solvay Pharmaceuticals, Inc. for LUVOX(R) CR (fluvoxamine maleate) Extended-Release Capsules, to support LUVOX CR launch expenses, and for general corporate purposes.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see http://www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the use of the proceeds from the debt expansion, the ability to increase the senior debt by an additional $30 million and the launch of LUVOX CR. Words and phrases such as "will," "plan," "is expected" and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Jazz Pharmaceuticals' current expectations. Forward-looking statements involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that the conditions applicable to the option to further expand the senior debt will not be satisfied in a timely manner, or at all, and risks related to when or whether commercial launch of LUVOX CR will occur and Jazz Pharmaceuticals' need for additional funding. These and other risk factors are discussed under "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 9, 2007. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
6. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
9. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... 2016 , ... Shimadzu Scientific Instruments (SSI) will be showcasing ... Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for ... stop by booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC ...
(Date:4/27/2016)... Virgin Islands (PRWEB) , ... April 27, 2016 ... ... Company Ltd. (d/b/a Biohaven) is pleased to announce the appointment of John Tilton as ... was an Executive Director and one of the founding commercial leaders responsible for ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... Global ... mutual endorsement of an Asia-Pacific Symposium as other research and development initiatives for potential ... Santiago officials and top Global Stem Cells Group executives began meeting to establish a ...
(Date:4/26/2016)... Mass. (PRWEB) , ... April 26, 2016 , ... ... has been selected as one of three finalists for the European Inventor Award ... EPO’s annual innovation prize will be announced at a ceremony in Lisbon on June ...
Breaking Biology Technology:
(Date:3/9/2016)... NEW YORK , March 9, 2016 ... current and future states of the RNA Sequencing (RNA ... in segments such as instruments, tools and reagents, data ... Analyze various segments of the RNA-Sequencing market such ... RNA-Sequencing services Identify the main factors affecting each segment ...
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI ... categories of Innovation, Research & Development, Leadership in Education, ... This is the 9 th year of the ... of companies and individuals from past years . ... on a pre-described set of criteria, by a panel ...
(Date:3/2/2016)... 2, 2016 http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ... "Global Biometrics as a Service Market ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced ... as a Service Market 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has ...
Breaking Biology News(10 mins):